Image
Recommendation
Anti-HER2 therapy – Indications #1
Offer adjuvant trastuzumab (with or without pertuzumab) for patients with at least T1c, HER2-positive breast cancer (given at 3-week intervals for 1 year) in combination with surgery, chemotherapy, and radiation therapy as appropriate.
Offer adjuvant trastuzumab for people with T1c and above HER2-positive invasive breast cancer, given at 3-week intervals for 1 year in combination with surgery, chemotherapy and radiotherapy as appropriate
How this guidance was developed
This recommendation was adapted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording (‘Offer’) indicative of a strong recommendation (using GRADE methods) by the source guideline authors. The source recommendation was adapted by adding ‘with or without pertuzumab’.
Anti-HER2 therapy – Indications #1
Recommendation
Offer adjuvant trastuzumab (with or without pertuzumab) for patients with at least T1c, HER2-positive breast cancer (given at 3-week intervals for 1 year) in combination with surgery, chemotherapy, and radiation therapy as appropriate.
Principles in action
Patient-centred care
Image
Discuss out of pocket costs
This recommendation was adapted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording (‘Offer’) indicative of a strong recommendation (using GRADE methods) by the source guideline authors. The source recommendation was adapted by adding ‘with or without pertuzumab’.